Novo Nordisk shares plunge 22% after CagriSema obesity drug trial results ...United Arab Emirates

CNBC - Economy
Novo Nordisk shares plunge 22% after CagriSema obesity drug trial results
Shares of Danish pharmaceutical giant Novo Nordisk plummeted more than 22% on Friday after reporting results in a late-stage trial that missed expectations.

Read More Details
Finally We wish PressBee provided you with enough information of ( Novo Nordisk shares plunge 22% after CagriSema obesity drug trial results )

Apple Storegoogle play

Also on site :